COVID-19, 2019 novel coronavirus disease, hydroxychloroquine, plasma concentration, sarcoidosis, France, Medicine, Infectious and parasitic diseases, RC109-216

Because of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine treatment and contracted COVID-19 despite adequate plasma concentrations.